Hypertensive crisis following mRNA COVID-19 vaccination in adolescents: two case reports
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
In response to the global coronavirus disease 2019 (COVID-19) pandemic, vaccines were developed and approved quickly. However, numerous cardiovascular adverse events have been reported. We present two adolescent cases who developed a hypertensive crisis following NT162b2 mRNA COVID-19 vaccination. Patient 1 was an 18-year-old male and his systolic blood pressure was 230 mmHg one day after the second vaccine. He was obese. No secondary cause of hypertension other than the vaccine was identi- fied. Patient 2 was an 18-year-old male who complained with palpitation after the first vaccine. His blood pressure was 178/109 mmHg. He had autosomal dominant polycystic kidney disease. Both were treated with continuous infusion of labetalol followed by losartan, and blood pressure was controlled. Patient 2 received second vaccination and his blood pressure did not rise. It is warranted to measure blood pressure in adolescents at high risk of hypertension after NT162b2 mRNA COVID-19 vaccination.
Abstract
In response to the global coronavirus disease 2019 (COVID-19) pandemic, vaccines were developed and approved quickly. However, numerous cardiovascular adverse events have been reported. We present two adolescent cases who developed a hypertensive crisis following NT162b2 mRNA COVID-19 vaccination. Patient 1 was an 18-year-old male and his systolic blood pressure was 230 mmHg one day after the second vaccine. He was obese. No secondary cause of hypertension other than the vaccine was identi- fied. Patient 2 was an 18-year-old male who complained with palpitation after the first vaccine. His blood pressure was 178/109 mmHg. He had autosomal dominant polycystic kidney disease. Both were treated with continuous infusion of labetalol followed by losartan, and blood pressure was controlled. Patient 2 received second vaccination and his blood pressure did not rise. It is warranted to measure blood pressure in adolescents at high risk of hypertension after NT162b2 mRNA COVID-19 vaccination.
참고문헌 (10)
- Raina R, "Hypertensive crisis in pediatric patients : an overview", Front Pediatr, 8, pp.58891~ (2020)
- Meylan S, "Stage III hypertension in patients after mRNA-based SARSCoV-2 vaccination", Hypertension, 77, pp.e56~e57 (2021)
- Athyros VG, "A possible case of hypertensive crisis with intracranial haemorrhage after an mRNA anti-COVID-19 vaccine", Angiology, 73, pp.87~ (2022)
- Kim MS, "Comparative safety of mRNA COVID-19 vaccines to influenza vaccines : a pharmacovigilance analysis using WHO international database", J Med Virol, 94, pp.1085~1095 (2022)
- Connors M, "SARS-CoV-2 vaccines:much accomplished, much to learn", Ann Intern Med, 174, pp.687~690 (2021)
- Pucci F, "Quantifying renin-angiotensin-system alterations in COVID-19", Cells, 10, pp.2755~ (2021)
- Mizuiri S, "ACE and ACE2 in kidney disease", World J Nephrol, 4, pp.74~82 (2015)
- Schrier RW, "Decade in review--polycystic kidney disease : slowing progression of autosomal dominant polycystic kidney disease", Nat Rev Nephrol, 11, pp.638~639 (2015)
- Hall JE, "Obesity, kidney dysfunction and hypertension: mechanistic links", Nat Rev Nephrol, 15, pp.367~385 (2019)
- Khani E, "Hypertensive crisis following COVID-19vaccination", J Clin Pharmacol, 62, pp.1047~1048 (2022)